Table S1. Descriptive statistics for KIF11 and KIF14 expression parameters.

| | **TUMOR** | | | | | | **ADJACENT** | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | MED | IQR | MIN | MAX | Mean | SD | MED | IQR | MIN | MAX | Mean | SD |
| KIF11 IS | 2 | 1-2 | 0 | 3 | 1.58 | 0.86 | 1 | 0-1 | 0 | 2 | 0.59 | 0.53 |
| KIF11 PS | 1 | 0-1.46 | 0 | 3 | 0.88 | 0.82 | 3 | 0-4 | 0 | 4 | 2.03 | 1.85 |
| KIF11 IRS | 1 | 0-2.23 | 0 | 9 | 1.54 | 1.82 | 3 | 0-4 | 0 | 4 | 2.06 | 1.87 |
| KIF14 IS | 1.5 | 1-2 | 0 | 3 | 1.70 | 0.70 | 1 | 1-1 | 0 | 2 | 0.98 | 0.40 |
| KIF14 PS | 4 | 3-4 | 0 | 4 | 3.40 | 0.85 | 4 | 4-4 | 0 | 4 | 3.42 | 1.26 |
| KIF14 IRS | 6 | 4-8 | 0 | 12 | 6.03 | 2.90 | 4 | 4-4 | 0 | 8 | 3.68 | 1.64 |

IS – immunointensity; PS - immunopercentage; IRS – immunoreactive score (IS x PS); med – median; IQR-interquartile range; min- minimum; max – maximum; SD – standard deviation.

Table S2. Univariate and multivariate Cox proportional hazards models for overall survival of TCGA patients with pancreatic adenocarcinoma.

| Variable | **Univariate analysis** | | | | **Multivariate analysis: KIF11+KIF14*** | | | | **Multivariate analysis: 5-gene panel**** | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | HR | 95% CI | | *P* | HR | 95% CI | | *P* | HR | 95% CI | | *P* |
| | | lower | upper | | | lower | upper | | | lower | upper | |
| *KIF11+KIF14** | 3.41 | 2.12 | 5.47 | **<0.0001** | 2.60 | 1.58 | 4.29 | **0.0002** | - | - | - | - |
| 5-gene panel** | 5.18 | 2.63 | 10.20 | **<0.0001** | - | - | - | - | 5.21 | 2.41 | 11.27 | **<0.0001** |
| *ASPM* (low vs. high) | 2.61 | 1.73 | 3.94 | **<0.0001** | - | - | - | - | - | - | - | - |
| *CEP55* (low vs. high) | 2.49 | 1.58 | 3.90 | **<0.0001** | - | - | - | - | - | - | - | - |
| *GAMT* (high vs. low) | 0.61 | 0.39 | 0.94 | **0.03** | - | - | - | - | - | - | - | - |
| Age (≤ 60 vs. ≥ 60) | 1.41 | 0.90 | 2.21 | 0.13 | 1.46 | 0.85 | 2.50 | 0.17 | 2.68 | 1.20 | 5.97 | **0.02** |
| Sex (female vs. male) | 0.81 | 0.54 | 1.23 | 0.33 | 0.92 | 0.56 | 1.49 | 0.72 | 1.00 | 0.50 | 2.05 | 0.99 |
| Grade (G1 vs. G2-G3) | 2.18 | 1.15 | 4.13 | **0.02** | 1.68 | 0.67 | 4.19 | 0.27 | 1.20 | 0.39 | 3.67 | 0.75 |
| pN (absent vs. present) | 2.10 | 1.25 | 3.52 | **0.005** | 2.45 | 1.28 | 4.69 | **0.01** | 4.37 | 1.49 | 12.80 | **0.01** |
| pT (T1-T2 vs. T3-T4) | 2.21 | 1.14 | 4.28 | **0.02** | 1.08 | 0.50 | 2.36 | 0.84 | 1.79 | 0.39 | 8.14 | 0.45 |

Significant p-values (p < 0.05) are marked in bold.
*n = 133; KIF11[low]/KIF14[low] vs. KIF11[high]/KIF14[high]
**n = 85; KIF11[low]/KIF14[low]/CEP55[low]/ASPM[low]/GAMT[high] *vs.* KIF11[high]/KIF14[high]/CEP55[high]/ASPM[high]/GAMT[low])
Abbreviations: CI, confidence interval; HR, hazard ratio; OS – overall survival; TCGA – The Cancer Genome Atlas. HR: adjusting for age, gender, histologic grade, pN, pT, and each marker separately. Owing to the strong correlations between *KIF11* and *KIF14* mRNA expression, they were not included in the same multivariate model.
'-' indicates variable was not included in multivariate Cox analysis.